Literature DB >> 22155484

Amniotic mesenchymal stem cells have robust angiogenic properties and are effective in treating hindlimb ischaemia.

Sung-Whan Kim1, Hong-Zhe Zhang, Chae Eun Kim, Hyun Sook An, Jong-Min Kim, Moo Hyun Kim.   

Abstract

AIMS: In this study, we aimed to evaluate whether human amniotic mesenchymal stem cells (AMMs) have angio-vasculogenic properties and to determine their therapeutic effects on experimental ischaemia. Although AMMs are a promising source of stem cells, their angio-vasculogenic properties are not fully understood. METHODS AND
RESULTS: We have characterized AMMs by quantitative real-time polymerase chain reaction, Matrigel tube formation assays, and various in vitro endothelial differentiation assays. AMMs expressed significantly higher levels of representative proangiogenic genes, vascular endothelial growth factor-A, angiopoietin-1, hepatocyte growth factor, and fibroblast growth factor-2 (FGF-2) than adipose-derived mesenchymal stem cells. In addition, the anti-apoptotic factor Akt-1 was highly expressed in the AMMs. Cells were directly transplanted into the ischaemic hindlimbs of mice to evaluate their angio-vasculogenic and therapeutic effects. They spontaneously differentiate into vascular-like structures and exhibit endothelial-specific genes and proteins. In an in vivo study on hindlimb ischaemia, implantation of AMMS augmented blood perfusion and capillary density, indicating AMM-augmented neovascularization. The engraftment rate of AMMs was high, and the transplanted AMMs showed vasulogenic potential.
CONCLUSION: AMMs are not only markedly angiogenic but also vasculogenic, thus ameliorating hindlimb ischaemia. Our data suggest that AMMs have considerable therapeutic effects on ischaemic hindlimb through high angiogenic and engraftment abilities.

Entities:  

Mesh:

Year:  2011        PMID: 22155484     DOI: 10.1093/cvr/cvr328

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  23 in total

1.  Transplantation of Human Amniotic Mesenchymal Stem Cells Promotes Functional Recovery in a Rat Model of Traumatic Spinal Cord Injury.

Authors:  Hong-Long Zhou; Xue-Jun Zhang; Mao-Ying Zhang; Zhong-Jie Yan; Zhi-Min Xu; Ru-Xiang Xu
Journal:  Neurochem Res       Date:  2016-06-28       Impact factor: 3.996

2.  Stem cells: a comprehensive review of origins and emerging clinical roles in medical practice.

Authors:  Salomon Poliwoda; Nazir Noor; Evan Downs; Amanda Schaaf; Abigail Cantwell; Latha Ganti; Alan D Kaye; Luke I Mosel; Caroline B Carroll; Omar Viswanath; Ivan Urits
Journal:  Orthop Rev (Pavia)       Date:  2022-08-25

3.  SDF-1-edited human amniotic mesenchymal stem cells stimulate angiogenesis in treating hindlimb ischaemia.

Authors:  Hong Zhe Zhang; Seongho Han; Sung-Whan Kim
Journal:  J Cell Mol Med       Date:  2022-05-26       Impact factor: 5.295

Review 4.  Mesenchymal Stem Cell Mechanisms of Action and Clinical Effects in Osteoarthritis: A Narrative Review.

Authors:  Vilim Molnar; Eduard Pavelić; Kristijan Vrdoljak; Martin Čemerin; Emil Klarić; Vid Matišić; Roko Bjelica; Petar Brlek; Ivana Kovačić; Carlo Tremolada; Dragan Primorac
Journal:  Genes (Basel)       Date:  2022-05-26       Impact factor: 4.141

5.  Restoration of Hydrogen Sulfide Production in Diabetic Mice Improves Reparative Function of Bone Marrow Cells.

Authors:  Zhongjian Cheng; Venkata Naga Srikanth Garikipati; Emily Nickoloff; Chunlin Wang; David J Polhemus; Jibin Zhou; Cynthia Benedict; Mohsin Khan; Suresh K Verma; Joseph E Rabinowitz; David Lefer; Raj Kishore
Journal:  Circulation       Date:  2016-09-22       Impact factor: 29.690

6.  Amniotic mesenchymal stem cells enhance wound healing in diabetic NOD/SCID mice through high angiogenic and engraftment capabilities.

Authors:  Sung-Whan Kim; Hong-Zhe Zhang; Longzhe Guo; Jong-Min Kim; Moo Hyun Kim
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

7.  Mesenchymal stem or stromal cells from amnion and umbilical cord tissue and their potential for clinical applications.

Authors:  Andrea Lindenmair; Tim Hatlapatka; Gregor Kollwig; Simone Hennerbichler; Christian Gabriel; Susanne Wolbank; Heinz Redl; Cornelia Kasper
Journal:  Cells       Date:  2012-11-12       Impact factor: 6.600

8.  CD13 promotes mesenchymal stem cell-mediated regeneration of ischemic muscle.

Authors:  M Mamunur Rahman; Jaganathan Subramani; Mallika Ghosh; Jiyeon K Denninger; Kotaro Takeda; Guo-Hua Fong; Morgan E Carlson; Linda H Shapiro
Journal:  Front Physiol       Date:  2014-01-09       Impact factor: 4.566

9.  COMP-Ang1 Potentiates EPC Treatment of Ischemic Brain Injury by Enhancing Angiogenesis Through Activating AKT-mTOR Pathway and Promoting Vascular Migration Through Activating Tie2-FAK Pathway.

Authors:  Hyo Eun Moon; Kyunghee Byun; Hyung Woo Park; Jin Hyun Kim; Jin Hur; Joong Shin Park; Jong Kwan Jun; Hyo-Soo Kim; Seung Leal Paek; In Keyoung Kim; Jae Ha Hwang; Jin Wook Kim; Dong Gyu Kim; Young Chul Sung; Gou-Young Koh; Chang W Song; Bonghee Lee; Sun Ha Paek
Journal:  Exp Neurobiol       Date:  2015-03-13       Impact factor: 3.261

10.  Amniotic mesenchymal stem cells display neurovascular tropism and aid in the recovery of injured peripheral nerves.

Authors:  YongNan Li; Longzhe Guo; Hyun Sook Ahn; Moo Hyun Kim; Sung-Whan Kim
Journal:  J Cell Mol Med       Date:  2014-04-08       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.